Nordic Nanovector Capital Markets Day 2015: Reiterates Its Commitment To Becoming A Significant Player In Oncology And Hematology

OSLO, Norway--(BUSINESS WIRE)--On 17 November 2015, Nordic Nanovector ASA (OSE:NANO) hosted its first Capital Markets Day in Oslo to provide investors, analysts and press with the opportunity to learn more about the Company’s corporate strategy, its lead product Betalutin®, a potential new treatment for non-Hodgkin’s lymphoma (NHL), its development and commercialisation plans, as well as future opportunities for value creation.

Help employers find you! Check out all the jobs and post your resume.

Back to news